RxDoctor Payments Data

David Allen, NP

Nurse Practitioner · Hixson, TNNPI 1770526709

Payments from drug & device makers

$8,199in general payments, 2019–2025

Across 471 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$732
  • AstraZeneca$587
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$553
  • Lilly USA, LLC$480
  • Otsuka America Pharmaceutical, Inc.$455
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,199 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$52,873
Medicare patients
162
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$161,827
FarxigaDapagliflozin Propanediol100$126,906
TrulicityDulaglutide57$103,215
JardianceEmpagliflozin60$79,833
EliquisApixaban57$46,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$35,759
XareltoRivaroxaban26$31,916
RexultiBrexpiprazole19$31,313
MounjaroTirzepatide16$18,767
Combivent RespimatIpratropium/Albuterol Sulfate17$17,438
TrintellixVortioxetine Hydrobromide18$15,774
LinzessLinaclotide19$14,602
Repatha SyringeEvolocumab17$10,611
EntrestoSacubitril/Valsartan13$10,533
Rosuvastatin Calcium528$7,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,679$161,82789 claims
AstraZenecaFarxiga$587$126,906100 claims
Lilly USA, LLCTrulicity, Mounjaro$480$121,98273 claims
Boehringer IngelheimJardiance, Combivent Respimat$281$97,27177 claims
PfizerEliquis$338$46,88657 claims
GSKTrelegy Ellipta, Incruse Ellipta$89$39,81745 claims
Otsuka America Pharmaceutical, Inc.Rexulti$455$31,31319 claims
AbbVieLinzess, Synthroid$732$16,11830 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$50$15,77418 claims
NovartisEntresto$164$10,53313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Hixson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →